Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents

University of Illinois at Chicago37 enrolled

Overview

The purpose of this study is to determine whether the LAP-BAND system is safe and effective in morbidly obese adolescents.

The aim of this research is to evaluate the safety and efficacy of the use of the Lap-Band system in the morbidly obese adolescent population in the United States. We also propose to take advantage of the opportunity for liver biopsy and the data collected for the FDA study in adolescents to answer several questions: 1) what is the true incidence of non-alcoholic fatty liver disease (NAFLD) and its variants in morbidly obese adolescents; 2) what is the course of the NAFLD disease in adolescents who have undergone weight loss, including the progression from steatosis to NASH/ fibrosis or the progression of NASH to cirrhosis? 3) What are the factors implicated in this progression and 4) Is there a link between the excess visceral fat, MS and NAFLD as assessed by parallel changes in metabolic syndrome (MS) and NAFLD following weight loss intervention. The LAPBAND may provide obese adolescents with a significantly less morbid and reversible surgical option for weight loss.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Morbid Obesity

Interventions

Placement of an adjustable gastric bandDEVICE

Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.

Eligibility

Sex: ALLMin age: 14 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ages 14 through 17 * BMI greater than 40 * BMI 35 to 40 and also having an obesity related comorbidity * Have a history of working in a multidisciplinary weight loss program utilizing nutritional training, behavior modification, and activity training Exclusion Criteria: * Subject history of congenital or acquired anomalies fo the gastrointestinal tract * Severe cardiopulmonary or other serious organic disease * Severe coagulopathy * Hepatic insufficiency or cirrhosis * History of bariatric gastric or esophageal surgery * History of intestinal obstruction or adhesive peritonitis * History of esophageal motility disorders * Type I diabetes

Locations (1)

UIMC

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Weight loss

Time frame: Every six months

Secondary Outcomes

Resolution of comorbidities

Time frame: every six months

Assess the status of comorbidities and changes in quality of life scores from baseline.

Time frame: every six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.